236 related articles for article (PubMed ID: 10594565)
21. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
22. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.
Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG
J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
25. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
26. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.
Jodo S; Kobayashi S; Kayagaki N; Ogura N; Feng Y; Amasaki Y; Fujisaku A; Azuma M; Yagita H; Okumura K; Koike T
Clin Exp Immunol; 1997 Jan; 107(1):89-95. PubMed ID: 9010262
[TBL] [Abstract][Full Text] [Related]
28. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia.
Kuwano K; Kawasaki M; Maeyama T; Hagimoto N; Nakamura N; Shirakawa K; Hara N
Chest; 2000 Aug; 118(2):451-8. PubMed ID: 10936140
[TBL] [Abstract][Full Text] [Related]
29. Alterations of Fas and Fas-related molecules in patients with silicosis.
Otsuki T; Miura Y; Nishimura Y; Hyodoh F; Takata A; Kusaka M; Katsuyama H; Tomita M; Ueki A; Kishimoto T
Exp Biol Med (Maywood); 2006 May; 231(5):522-33. PubMed ID: 16636300
[TBL] [Abstract][Full Text] [Related]
30. Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants.
Hosaka N; Oyaizu N; Than S; Pahwa S
Clin Immunol; 2000 Apr; 95(1 Pt 1):20-5. PubMed ID: 10794428
[TBL] [Abstract][Full Text] [Related]
31. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1.
Sakamoto N; Mukae H; Fujii T; Kakugawa T; Kaida H; Kadota J; Kohno S
Respir Med; 2004 Mar; 98(3):213-9. PubMed ID: 15002756
[TBL] [Abstract][Full Text] [Related]
32. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
33. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis.
Kuwano K; Hagimoto N; Kawasaki M; Nakamura N; Shirakawa K; Maeyama T; Hara N
Int Arch Allergy Immunol; 2000 Jul; 122(3):209-15. PubMed ID: 10899765
[TBL] [Abstract][Full Text] [Related]
34. Soluble Fas/FasLare elevated in the serum and cerebrospinal fluid of patients with neurocysticercosis.
Chen X; Yu X; Wang Y; Zhu J; Gu J
Parasitol Res; 2017 Nov; 116(11):3027-3036. PubMed ID: 28965226
[TBL] [Abstract][Full Text] [Related]
35. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Br J Ophthalmol; 2000 Oct; 84(10):1130-4. PubMed ID: 11004098
[TBL] [Abstract][Full Text] [Related]
36. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
37. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
38. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
39. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
40. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
